Corporate venturing unit Shire Strategic Investment has led the latest investment in biotech company Promedior. They close their D round at $24.5m
Promedior, a US-based biotech company developing therapeutics for the treatment of fibrosis, has closed its Series D round at $24.5m, having just added a $3m investment from corporate venture capital firm Shire Strategic Investment Group. Promedior received $21.5m in July of this year led by Fibrotic Ventures. Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.